CLOSTRIDIUM DIFFICILE IMMUNOGENE ZUSAMMENSETZUNG

European patent · EP3160500 · In force

Register entry

Publication number
EP3160500
Application number
EP15733404
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 25, 2015
Published
May 3, 2017
Granted
Aug 21, 2019
Protection ends at the latest
Jun 24, 2035
Next annual fee due
Jun 30, 2027
IPC classes
A61K 39/08 (2006.01)
C07K 14/33 (2006.01)
Priority
GB 201411306 25.06.2014
GB 201411371 26.06.2014
PCT application
PCT/EP2015/064324 25.06.2015
PCT publication
WO2015/197737 30.12.2015
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  4. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  5. Jul 1, 2022

    Change

    Published in Swissreg on 01.07.2022

  6. Sep 12, 2019

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich

    Published in Swissreg on 12.09.2019

  7. Aug 21, 2019

    Granted

    Published in Swissreg on 21.08.2019

Parties

Holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89, 1330 Rixensart, BE

Agent

Isler & Pedrazzini AG

Postfach 1772, 8027 Zürich

Inventor

CASTADO, Cindy

B-1330 Rixensart, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.